Scholarlink

<p>This study compared the efficacy and toxicity of two cytarabine doses (1&#xa0;g/m² vs. 2&#xa0;g/m²) within the CLAG regimen for relapsed/refractory acute myeloid leukemia (R/R AML) patients. In this multicenter retrospective analysis, 183 R/R AML patients received the CLAG regimen (86 in the 1 g/m² group; 97 in the 2 g/m² group). After excluding 12 unevaluable cases, 171 patients (82 vs. 89) were analyzed. Propensity score matching (PSM) created 102 well-balanced pairs. Endpoints included complete remission rate (CRR), overall remission rate (ORR), overall survival (OS), leukemia-free survival (LFS), and toxicity. A significantly higher complete response (CR) rate was observed in the 2 g/m² group compared with the 1 g/m² group, both in the overall population (71.9% vs. 53.7%; p = 0.013) and in the propensity score-matched (PSM) cohort (68.6% vs. 49.0%; p = 0.044). The 2 g/m² regimen was also associated with superior 2-year overall survival (OS) in the overall analysis (46.2% vs. 13.4%; p = 0.004), with a strong trend toward significance in the PSM cohort (33.9% vs. 13.7%; p = 0.07). Toxicity profiles were similar except for a longer neutropenia duration in the 2 g/m² group (18 vs. 16 days, p = 0.003). Allogeneic HSCT post-remission was a significant predictor for improved OS. The 2 g/m² cytarabine dose in the CLAG regimen yielded superior response rates and survival outcomes in R/R AML patients eligible for transplant bridging, without increasing significant toxicity.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

2g/m2 Ara-c induced more favorable outcome than 1g/m2 Ara-c in CLAG treatment for refractory or relapsed acute myeloid leukemia without increase toxicity: a multicenter propensity score matching analysis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月23日

查看全文
  • Na liu,
  • Yan-ru Ma,
  • Jia-nan Pang,
  • Meng -wei Sun,
  • Yao sun,
  • Ying-jie Liu,
  • Jiang-wei Hu,
  • Yu-hang li,
  • Zhuo-qing Qiao,
  • Ming-hui Duan,
  • Su-jun Gao,
  • Qian Jiang,
  • Liang-ding Hu

摘要

This study compared the efficacy and toxicity of two cytarabine doses (1 g/m² vs. 2 g/m²) within the CLAG regimen for relapsed/refractory acute myeloid leukemia (R/R AML) patients. In this multicenter retrospective analysis, 183 R/R AML patients received the CLAG regimen (86 in the 1 g/m² group; 97 in the 2 g/m² group). After excluding 12 unevaluable cases, 171 patients (82 vs. 89) were analyzed. Propensity score matching (PSM) created 102 well-balanced pairs. Endpoints included complete remission rate (CRR), overall remission rate (ORR), overall survival (OS), leukemia-free survival (LFS), and toxicity. A significantly higher complete response (CR) rate was observed in the 2 g/m² group compared with the 1 g/m² group, both in the overall population (71.9% vs. 53.7%; p = 0.013) and in the propensity score-matched (PSM) cohort (68.6% vs. 49.0%; p = 0.044). The 2 g/m² regimen was also associated with superior 2-year overall survival (OS) in the overall analysis (46.2% vs. 13.4%; p = 0.004), with a strong trend toward significance in the PSM cohort (33.9% vs. 13.7%; p = 0.07). Toxicity profiles were similar except for a longer neutropenia duration in the 2 g/m² group (18 vs. 16 days, p = 0.003). Allogeneic HSCT post-remission was a significant predictor for improved OS. The 2 g/m² cytarabine dose in the CLAG regimen yielded superior response rates and survival outcomes in R/R AML patients eligible for transplant bridging, without increasing significant toxicity.